CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

Commercialization in China through partnership with SciClone Pharmaceuticals Expands access to potentially life-saving antibiotic  in the world's second-largest pharmaceutical market NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited.